Synthetic Eye 'EverPatch' Tissue Approved by FDA to Tackle Global Donor Shortage

The FDA has recently approved an Israeli-made synthetic eye tissue substitute, providing a solution to the worldwide shortage of donor tissue.

CorNeat Vision, an Israeli startup, has developed the CorNeat EverPatch, a non-degradable synthetic tissue designed explicitly for ophthalmic surgery.

The field of eye surgery stands to be revolutionized by EverPatch, as it promises to eliminate the necessity for donor tissue and the inherent risk of disease transmission.

The CorNeat EverPatch

NoCamels.com reports that the CorNeat EverPatch, made from a polymer that stimulates cellular acceptance and incorporation into eye tissue, primarily reinforces the sclera, the white outer layer of the eyeball.

Unlike traditional patching methods that rely on preserved and processed tissue, the EverPatch offers a sterile and non-degradable alternative.

By leveraging its proprietary EverMatrix technology, initially developed for CorNeat Vision's corneal prosthesis program, the company has created a synthetic tissue that significantly advances ocular surgery.

Almog Aley-Raz, CEO and VP of R&D of CorNeat Vision, expressed his excitement about introducing the CorNeat EverPatch to the US market.

In a press release, he stated, "EverMatrix presents a significant business opportunity as it is the only synthetic non-degradable patch material in ocular surgery."

Aley-Raz also emphasized the broader potential of the biocompatible material, suggesting its application in soft tissue reinforcement, biomechanical integration of implants with surrounding tissue, fabrication of membranes, and concealment of implants and sensors.

Dr. Gilad Litvin, CorNeat Vision's Chief Medical Officer and Co-Founder, highlighted the advantages of the EverPatch over traditional patching materials.

"The CorNeat EverPatch was designed with the goals of being long-lasting, sterile, immunologically inactive, cosmetically acceptable, and readily available. It provides better handling, is significantly thinner than processed patch tissue, and has holes that allow for accurate positioning and anchoring," said Dr. Litvin.

Nationwide Expansion

This synthetic tissue substitute offers a viable alternative to traditional patching methods by addressing the critical needs of ocular surgeons worldwide.

With its innovative design and potential applications beyond ophthalmic surgery, the EverPatch has the potential to revolutionize the field and transform patient care.

The CorNeat EverPatch will be initially launched in leading ophthalmic centers in the US in the third quarter of 2023, with plans for nationwide expansion later in the year.

The introduction of EverPatch represents a significant step forward in ensuring the availability of sterile, non-degradable synthetic tissue for ophthalmic surgeries and addressing the global donor shortage.

What's In the News

The approval of the CorNeat EverPatch by the FDA marks a significant advancement in the field of ocular surgery. This synthetic, non-degradable tissue substitute offers a sterile and reliable solution to the scarcity of donor tissue worldwide.

With its potential for broader use in various medical applications, the EverPatch paves the way for improved patient outcomes and further advancements in health technology.

Stay posted here at Tech Times.